Literature DB >> 24417906

[Comparison of the M and XL FibroScan(®) probes to estimate liver stiffness by transient elastography].

José Ignacio Herrero1, Mercedes Iñarrairaegui2, Delia D'Avola2, Bruno Sangro2, Jesús Prieto2, Jorge Quiroga2.   

Abstract

The FibroScan(®) XL probe has been specifically designed for obese patients to measure liver stiffness by transient elastography, but it has not been well tested in non-obese patients. The aim of this study was to compare the M and XL FibroScan(®) probes in a series of unselected obese (body mass index above 30 kg/m(2)) and non-obese patients with chronic liver disease. Two hundred and fifty-four patients underwent a transient elastography examination with both the M and XL probes. The results obtained with the two probes were compared in the whole series and in obese (n=82) and non-obese (n=167) patients separately. The reliability of the examinations was assessed using the criteria defined by Castéra et al. The proportion of reliable exams was significantly higher when the XL probe was used (83% versus 73%; P=.001). This significance was maintained in the group of obese patients (82% versus 55%; P<.001), but not in the non-obese patients (84% versus 83%). Despite a high correlation between the stiffness values obtained with the two probes (R=.897; P<.001), and a high concordance in the estimation of fibrosis obtained with the two probes (Cronbach's alpha value: 0.932), the liver stiffness values obtained with the XL probe were significantly lower than those obtained with the M probe, both in the whole series (9.5 ± 9.1 kPa versus 11.3 ± 12.6 kPa; P<0.001) and in the obese and non-obese groups. In conclusion, transient elastography with the XL probe allows a higher proportion of reliable examinations in obese patients but not in non-obese patients. Stiffness values were lower with the XL probe than with the M probe.
Copyright © 2013 Elsevier España, S.L. and AEEH y AEG. All rights reserved.

Entities:  

Keywords:  Elastografía; Elastography; Fibrosis hepática; Liver fibrosis; Liver stiffness; Obesidad; Obesity; Rigidez hepática

Mesh:

Year:  2014        PMID: 24417906     DOI: 10.1016/j.gastrohep.2013.10.009

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  5 in total

1.  Factors Associated with the Quality of Transient Elastography.

Authors:  Eva Juárez-Hernández; Martha Helena Uribe-Ramos; Martha Helena Ramos-Ostos; Angélica Yanine López-Ramírez; Sofía Ornelas-Arroyo; Juan Luis Romero-Flores; Nahúm Méndez-Sánchez; Misael Uribe; Norberto C Chávez-Tapia
Journal:  Dig Dis Sci       Date:  2015-03-11       Impact factor: 3.199

Review 2.  Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ma Ai Thanda Han; Rola Saouaf; Walid Ayoub; Tsuyoshi Todo; Edward Mena; Mazen Noureddin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-03-09       Impact factor: 5.045

3.  Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C.

Authors:  L C Mendes; P A Ferreira; N Miotto; L Zanaga; E Gonçales; M S Lazarini; F L Gonçales; R S B Stucchi; A G Vigani
Journal:  Braz J Med Biol Res       Date:  2016-08-01       Impact factor: 2.590

4.  Aspartate aminotransferase to platelet ratio can reduce the need for transient elastography in Chinese patients with chronic hepatitis B.

Authors:  Wei Yue; Yan Li; Jiawei Geng; Ping Wang; Li Zhang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

5.  Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.

Authors:  Taisa Grotta Ragazzo; Denise Paranagua-Vezozzo; Fabiana Roberto Lima; Daniel Ferraz de Campos Mazo; Mário Guimarães Pessoa; Claudia Pinto Oliveira; Venancio Avancini Ferreira Alves; Flair José Carrilho
Journal:  Clinics (Sao Paulo)       Date:  2017-10       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.